Articles Tagged with Male Breast Growth

If you file a Risperdal lawsuit, there is guarantee that you will win a trial verdict or obtain a settlement. But based on previous cases, it appears that the makers of Risperdal may be motivated to settle claims in order to avoid revealing information that may lead to more lawsuits or avoid trial verdicts.

Aron Banks was the first person to take his Risperdal personal injury claim to trail against the drug manufacturer. Banks was prescribed Risperdal when he was nine years old even though the drug wasn’t approved for use by children at the time. He experienced rapid weight gain, suffered injury to his endocrine system and experienced psychological trauma. He also developed breasts large enough to require surgery to remove them, a condition known as Gynecomastia.

In September 2012, the makers of Risperdal decided agreed to settle Banks case under the condition that neither Banks nor his attorney would reveal the amount. But his attorney did tell the media that he believed “the possibility of more evidence of off-label marketing and improper conduct by Johnson & Johnson had something to do with the settlement.”

Multiple lawsuits have been filed in the United States against the makers of Risperdal for failing to warn patients that it may cause male breast growth, a condition known as Gynecomastia.

Risperdal was approved for sale in the United States in 1993 by the Food and Drug Administration (FDA). It commonly used to treat irritability in people with autism, schizophrenia, and bipolar disorder.

The makers of Risperdal began marketing the drug to treat children as early as 2003, years before the FDA approved such action by the drug-maker. The makers of Risperdal also recently faced accusations that it was paying physicians to speak favorably of the drug, sponsor golf outings, and offering other incentives encouraging doctors to prescribe Risperdal to adolescents and children.